BioSpace News Archive

Business

OnQuality Pharma Raises $20 Million to Support Ongoing Oncodermatology Trial

The trial assesses the safety and efficacy of a targeted supportive care agent that addresses the specific side effects of vascular endothelial growth factor receptor (VEGFR) inhibitors among cancer patients.

March 31, 2021
·
4 min read
·
Gail Dutton
Business

Biopharma Companies Shuffle Locations, Moving or Cutting Jobs in the Process

As biopharma companies focus on efficiencies and close sites, jobs are getting lost. Here’s a look.

March 31, 2021
·
3 min read
·
Mark Terry
Business

QED Therapeutics and Helsinn Group Team Up to Co-Develop Cancer Drug

QED Therapeutics, an affiliate of BridgeBio Pharma, announced today their global collaboration and licensing agreement with Helsinn Group.

March 31, 2021
·
2 min read
·
Kristiane Polido
Where Do You Stand on Employer-Mandated Vaccines?

What are your thoughts on companies mandating COVID-19 vaccines for employees? Are you open to getting vaccinated? Or are you still waiting for more research to be done on the different options?

March 31, 2021
·
3 min read
·
Porschia Parker-Griffin
BioCapital

Precigen CEO Envisions a Transformative 2021 with Precision Medicine Therapy

The year 2020 and the COVID-19 pandemic created a number of challenges for individuals and companies. Despite these hurdles, Maryland-based Precigen still managed to achieve its clinical milestones in oncology.

March 31, 2021
·
4 min read
·
Alex Keown
Global Roundup: Astellas Eyes European Approval of Urothelial Cancer Drug

Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

March 31, 2021
·
6 min read
·
Alex Keown
Business

Former Gilead Sciences CEO, Chairman John Martin Dies at 70

John Martin, the chief executive officer who turned Gilead Sciences into a powerhouse company with treatments for hepatitis and HIV, died. He was 70 years old. A cause of death has not been announced.

March 31, 2021
·
2 min read
·
Alex Keown
Drug Development

Pfizer-BioNTech: COVID-19 Vaccine “100% Effective” in Adolescents

The two companies announced data from a Phase III study which showed 100% efficacy and robust antibody responses in patients ages 12 -15 who received the BNT162b2 vaccine.

March 31, 2021
·
4 min read
·
Alex Keown
Genetown

Pyxis Bags $152 Million to Advance ADCs Licensed from Pfizer, LegoChem

Pyxis Oncology raised $152 million in a Series B financing round to advance its differentiated portfolio of antibody-drug conjugates licensed from Pfizer earlier this month.

March 31, 2021
·
2 min read
·
Alex Keown
Business

Former Merck Exec Joins Flagship to Helm AI Startup Generate Biomedicines

Michael T. Nally became the latest Merck executive to join Flagship Pioneering, taking the reins of its machine learning protein therapy company Generate Biomedicines.

March 31, 2021
·
2 min read
·
Mark Zipkin